Abbisko Cayman Limited (2256.HK)

3,250 -0,020 (-0,61%) Börsenschluss: 04:08PM HKT

Abbisko Cayman Limited

Building 3
No. 898 Halei Road Zhangjiang Hi-Tech Park Pudong New Area
Shanghai
China
86 21 6891 2098
https://www.abbisko.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 258

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Yao-Chang Xu	Founder, Chairman of the Board & CEO	11,37M	N/A	1957
Dr. Hongping Yu	Co-Founder, Joint Company Secretary, Senior VP-Chemistry, Chief Scientific Officer & Exe. Director	3,66M	N/A	1968
Dr. Zhui Chen	Co-Founder, Senior VP of Biology, Chief Scientific Officer & Executive Director	7,08M	N/A	1974
Dr. Zidong Zhang	Chief Financial Officer	N/A	N/A	1981
Ms. Jia Feng	VP of HR and Operations & Head of Human Resource	N/A	N/A	N/A
Mr. Yongyi Li	General Counsel	N/A	N/A	1976
Dr. Zhen Zhang	VP of CMC & Head of Chemistry, Manufacturing and Controls	N/A	N/A	1973
Dr. Jing Ji	Chief Medical Officer	N/A	N/A	1970
Ms. Yin Wah Chan FCCA, FCIS, FCS, HKICS	Joint Company Secretary	N/A	N/A	1975

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in HKD.

Beschreibung

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

Abbisko Cayman Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.